Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice.
Advances in supportive care have increased the likelihood that previously less common adverse effects of chemotherapy will be more evident. The incidence of chemotherapy-induced peripheral neuropathy (CIPN) is increasing because more neurotoxic drugs have been developed and because patients are living longer and receiving multiple chemotherapy regimens. This article reviews the anatomy of the peripheral nervous system, the proposed mechanisms of CIPN, and manifestations of CIPN from vinca alkaloids, taxanes, and platinum analogs. Major topics of this article are evidence-based data regarding symptom management, a review of medical management, and a synthesis of nursing care for patients at risk for or experiencing CIPN.
Wickham
Rita
R
Rush University Medical Center, Chicago, IL, USA. ritawickham@comcast.net
D000970:Antineoplastic Agents / Q000009:adverse effects*; D016903:Drug Monitoring / Q000451:nursing; D006801:Humans; D015994:Incidence; D024802:Nurse's Role; D009730:Nursing Assessment; D009859:Oncology Nursing / Q000458:organization & administration*; D010347:Patient Care Planning; D010353:Patient Education as Topic; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy*; D017671:Platinum Compounds / Q000009:adverse effects; D012307:Risk Factors; D012720:Severity of Illness Index; D013116:Spinal Cord / Q000033:anatomy & histology; D013126:Spinal Nerve Roots / Q000033:anatomy & histology; D043823:Taxoids / Q000009:adverse effects; D014748:Vinca Alkaloids / Q000009:adverse effects
D000970:Antineoplastic Agents; D017671:Platinum Compounds; D043823:Taxoids; D014748:Vinca Alkaloids